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Long noncoding RNAs (lncRNAs) are an emerging class of oncogenic molecules implicated in a diverse range of
human malignancies. We recently identified SChLAP1 as a novel lncRNA that demonstrates outlier expression in a
subset of prostate cancers, promotes tumor cell invasion and metastasis, and associates with lethal disease.
Based on these findings, we sought to develop an RNA in situ hybridization (ISH) assay for SChLAP1 to 1)
investigate the spectrum of SChLAP1 expression from benign prostatic tissue to metastatic castration-resistant
prostate cancer and 2) to determine whether SChLAP1 expression by ISH is associated with outcome after radical
prostatectomy in patients with clinically localized disease. The results from our current study demonstrate that
SChLAP1 expression increases with prostate cancer progression, and high SChLAP1 expression by ISH is
associated with poor outcome after radical prostatectomy in patients with clinically localized prostate cancer by
both univariate (hazard ratio = 2.343, P = .005) and multivariate (hazard ratio = 1.99, P = .032) Cox regression
analyses. This study highlights a potential clinical utility for SChLAP1 ISH as a novel tissue-based biomarker assay
for outcome prognostication after radical prostatectomy.
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Table 1. Clinicopathologic Characteristics of 160 Patients with Clinically Localized Prostate
Cancer Treated by Radical Prostatectomy.
Age, y
≤60 86 (53.8%)
N60 74 (46.2%)
GS
b7 41 (25.6%)
=7 109 (68.1%)
N7 10 (6.3%)
Tumor size, cm
b1 25 (15.6%)
≥1 135 (84.4%)
AJCC T stage
pT2a 19 (11.9%)
pT2b 103 (64.4%)
pT3a 31 (19.4%)
pT3b 6 (3.8%)
pT4 1 (0.6%)
Surgical margin
Negative 114 (71.2%)
Positive 46 (28.8%)
Preoperative PSA, ng/ml
b4 22 (13.8%)
4-7 68 (42.5%)
N7 70 (43.8%)
PSA recurrence
No 109 (68.1%)
Yes 51 (31.9%)
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In the era of prostate-specific antigen (PSA) screening, prostate cancer
has a varied clinical course. The majority of tumors are detected early
and are usually cured by definitive treatment with radical prostatec-
tomy or radiotherapy. However, even among those with definitively
treated, clinically localized prostate cancer, subsets of patients will
eventually progress and develop metastatic, castration-resistant
prostate cancer (mCRPC)—a disease which is nearly always lethal.
Standard pathologic evaluation of radical prostatectomy specimens
provides basic risk stratification for prostate cancer progression;
however, even these parameters may fail to accurately predict outcome
of a proportion of high-risk tumors. With this in mind, considerable
discovery efforts have focused on delineating tissue-based prognostic
biomarkers for prostate cancer—with little overall success [1].
To date, the majority of biomarker efforts have focused on protein-
coding genes, which comprise only a subset of all transcribed genes
[2,3]. Among the more than 90% of transcription that generates
noncoding genes, long noncoding RNAs (lncRNAs) most closely
resemble protein-coding genes in that they are transcribed by RNA
polymerase II, polyadenylated, and associated with specific epigenetic
signatures (i.e., H3K4me3 at the promoter and H3K36me3
throughout the gene length) [4,5]. Although the precise molecular
functions of lncRNAs remain poorly understood, an emerging body
of evidence indicates that lncRNAs have essential oncogenic roles in a
variety of tumor types, suggesting potential utility for clinical assays
that detect lncRNA expression.
Using transcriptome sequencing, we recently identified a set of 121
novel lncRNAs that were differentially expressed in prostate cancer
versus normal tissue or demonstrated outlier expression in a subset of
prostate cancers [6]. SChLAP1, an lncRNA that is highly overexpressed
in a subset of prostate cancers and associated with lethal disease, is
involved in tumor cell invasion and metastasis [7]. In a limited number
of samples, our preliminary data indicate that SChLAP1 expression
levels can be detected in formalin-fixed, paraffin-embedded (FFPE)
tissue sections by RNA in situ hybridization (ISH), suggesting potential
utility of SChLAP1 as a tissue-based prostate cancer biomarker.
Based on these initial findings, we sought to determine SChLAP1
expression by ISH on FFPE tissue in a cohort of patients with
clinically localized prostate cancer and lethal mCRPC. We identified
a subset of clinically localized prostate cancer patients with high
SChLAP1 expression; these patients are associated with high-risk
clinicopathologic features (e.g., high Gleason score [GS], seminal
vesicle invasion), decreased time to PSA recurrence after radical
prostatectomy, and poor clinical outcome after univariate and
multivariate Cox regression analyses. In addition, high SChLAP1
expression is detected in a significant proportion of patients with
lethal mCRPC. Overall, our results demonstrate suitability of
SChLAP1 ISH for the detection of aggressive prostate cancers and
indicate that SChLAP1 is a promising tissue-based prognostic
biomarker for prostate cancer.
Material and Methods
This study was approved by the University of Michigan (Ann Arbor)
Health Sciences Institutional Review Board, and all patients provided
written informed consent.
Tissue Microarray (TMA) Construction
TMAs comprised of surgical pathology material from 208 patients
with clinically localized prostate cancer were constructed using tumorand benign tissue from radical prostatectomy specimens; all patients
had undergone radical prostatectomy at the University of Michigan
Health System as primary monotherapy (i.e., no neoadjuvant
hormonal or radiation therapy). This radical prostatectomy series is
part of the University of Michigan Prostate Cancer Specialized
Program of Research Excellence Tissue Core. Three tissue cores (each
0.6 mm in diameter) were obtained from representative FFPE tissue
blocks for each included patient sample. Detailed clinicopathologic
data for this cohort (summarized in Table 1) are updated and
maintained on a secure relational database.
Similarly, TMAs comprised of rapid autopsy material from 60
patients with lethal mCRPC were constructed; this material was
obtained as part of the University of Michigan Prostate Cancer
Specialized Program of Research Excellence Rapid Autopsy Program, as
described previously [8]. All patients received multimodal therapy,
including a combination of radical prostatectomy, hormone depriva-
tion, radiation, and/or chemotherapy; detailed clinicopathologic data
for a portion of this cohort have been reported previously [9]. As
described above, three tissue cores (each 0.6 mm in diameter) were
obtained from representative FFPE tissue blocks from all metastatic
tumor sites, as well as primary tumor within the prostate (when present
at the time of autopsy; i.e., no prior radical prostatectomy).
SChLAP1 ISH
SChLAP1 ISH was performed on thin (approximately 4 µm thick)
TMA sections (Advanced Cell Diagnostics, Inc., Hayward, CA), as
described previously [7]; in parallel, SChLAP1 ISH was performed on
previously identified positive and negative control FFPE tissue
sections, and all controls worked adequately (data not shown). All
slides were examined for SChLAP1 ISH signals in morphologically
intact cells and scored manually by a study pathologist (R.M.).
Specific SChLAP1 ISH signal was identified as brown, punctate dots,
and expression level was scored as follows: 0 = no staining or less than
1 dot per 10 cells, 1 =1 to 3 dots per cell, 2 =4 to 9 dots per cell (few
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clusters), and 4 = greater than 15 dots per cell (more than 10% in dot
clusters). For each evaluable tissue core, a cumulative ISH product score
was calculated as the sum of the individual products of the expression
level (0 to 4) and percentage of cells (0 to 100) (i.e., [A%×0] + [B%×1] +
[C% × 2] + [D% × 3] + [E% × 4]; total range =0 to 400). For each
tissue sample, the ISH product score was averaged across evaluable
TMA tissue cores.
Statistical Methods
All statistical analyses were performed using R (version 3.0.2).
Mean SChLAP1 expression for benign prostatic glands, clinically
localized prostate cancer, and mCRPC were compared using the
Student’s t test and analysis of variance. The relationship between
SChLAP1 expression (low versus high; see Results section below) and
PSA recurrence in patients with clinically localized prostate cancer was
examined using the “survival” package in R. Briefly, the PSA
recurrence event time was calculated as the date of radical
prostatectomy to the time of serum PSA recurrence. (Patients
without PSA recurrence were censored on the date of last follow-up.)
The probability of PSA recurrence-free survival was then calculated
using the Kaplan-Meier product limit method, and the log-rank test
was used to compare the survival curves between low– and high–
SChLAP1 expression groups. To test for association betweenFigure 1. Spectrum of SChLAP1 expression in benign prostatic glan
SChLAP1 expression in (A) benign prostatic glands, (B) low- and (C)
SChLAP1 expression varies from negative to low in benign prostatic
expression in a subset of high-grade, clinically localized prostate cance
(D) = magnification, ×400.SChLAP1 expression and specific clinicopathologic features in
clinically localized prostate cancer, Fisher exact test and the Student’s
test were used for categorical and continuous data, respectively.
Finally, Cox proportional hazard univariate and multivariate
regression models were used to calculate the hazard ratio and
associated 95% confidence intervals for SChLAP1 expression and
specific clinical variables (e.g., extraprostatic extension), and the
statistical significance of Cox models covariate hazard ratios was
determined by Wald test.
Results and Discussion
SChLAP1 Expression Increases with Prostate Cancer Progression
To determine its association with prostate cancer progression, we
examined SChLAP1 expression by ISH in TMA cohorts of patients
with clinically localized prostate cancer or lethal mCRPC. Benign
prostate glands, clinically localized prostate cancer, and mCRPC
demonstrated a spectrum of SChLAP1 expression by ISH (Figure 1).
When present, SChLAP1 staining was predominantly nuclear
(Figure 1). Overall, there were significant differences in SChLAP1
expression between benign prostatic glands, clinically localized
prostate cancer, and lethal mCRPC (P b .001; Figure 2A). Benign
prostatic glands were available for evaluation in 74 patients with
clinically localized prostate cancer and, overall, showed absent to lowds, clinically localized prostate cancer, and lethal mCRPC by ISH.
high-GS clinically localized prostate cancer, and (D) lethal mCRPC.
glands and low-grade, clinically localized prostate cancers to high
rs and lethal mCRPC. Magnification, ×100. Inset in (A), (B), (C), and
Figure 2. SChLAP1 expression increases with prostate cancer
progression. (A) Histogram representation of mean SChLAP1 ISH
product score for benign prostatic glands (Benign), clinically
localized prostate cancer (PCA), and lethal mCRPC (METS) in a
large TMA cohort. Error bars represent standard deviation.
SChLAP1 expression is significantly associated with prostate
cancer progression, from benign glands to clinically localized
prostate cancer to mCRPC (P b .001). (B) Histogram representation
of proportion of clinically localized prostate cancer with negative
(ISH product score = 0), low (ISH product score N0 and b100), or
high (ISH product score ≥100) SChLAP1 expression, stratified by
GS. High SChLAP1 expression is associated with increasing GS in
clinically localized prostate cancer.
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100). Out of a total of 208 patients with clinically localized prostate
cancer, tissue from 160 patients (76.9%) was available for SChLAP1
expression evaluation (Table 1). Of these, 58 (36.3%) showed no
SChLAP1 expression (ISH product score = 0), whereas the remaining
102 (63.7%) demonstrated a wide spectrum of SChLAP1 expression
(overall mean ISH product score = 44.5; range = 0 to 337; Figure 1).
Relative to benign prostatic glands, SChLAP1 expression was
significantly increased in clinically localized prostate cancer (P b .001;
Figure 2A). In addition, high SChLAP1 expression was associated with
an increased proportion of clinically localized tumors with highGS (≥8;
Figure 2B). Rapid autopsy material from a total of 28 patients with
lethal mCRPC was available for SChLAP1 expression evaluation, and alarge proportion of the patients (15 cases, 53.6%) demonstrated high
SChLAP1 expression at one or more tissue sites. Relative to benign
prostatic glands (P b .001) and clinically localized prostate cancer (P b
.001), SChLAP1 expression was significantly increased in lethal
mCRPC (mean ISH product score = 136.4; range =0 to 370;
Figure 2A). Overall, these data indicate that SChLAP1 expression is
associated with prostate cancer progression.
High SChLAP1 Expression in Clinically Localized Prostate
Cancer Is Associated with High-Risk Clinicopathologic Features
and Poor Clinical Outcome
To investigate the relationship between SChLAP1 expression and
PSA recurrence after radical prostatectomy, we performed logistic
regression with the ISH product score and plotted the data as a
receiver operating characteristic curve (area under the curve = 0.668;
Figure 3A). In this model, the threshold which maximizes the sum of
sensitivity and specificity corresponds to a SChLAP1 ISH product
score of 100.9. Hence, we used an ISH product score of 100
(rounded down from 100.9 for practicality and convenience) to
differentiate patients with low and high SChLAP1 expression in our
clinically localized prostate cancer cohort. Comparing these groups
revealed that high SChLAP1 expression is associated with signifi-
cantly decreased time to PSA recurrence after radical prostatectomy
(P = .004; Figure 3B). Next, we evaluated the association between
SChLAP1 expression by ISH and standard clinicopathologic
parameters in our TMA cohort of clinically localized prostate cancer.
In these patients, high SChLAP1 expression is associated with several
high-risk clinicopathologic features, including high GS (≥8) and
seminal vesicle invasion (P b .05; Table 2 and Figure 3C ). Finally, by
both univariate (hazard ratio = 2.343, P = .005) and multivariate
(hazard ratio = 1.99, P = .032) Cox regression analyses, high
SChLAP1 expression was associated with poor clinical outcome in
clinically localized prostate cancer (Figure 3C, Tables 3 and 4). We
performed permutation tests to validate our selection of the cutoff of
ISH scores and found very little inflation of type-I errors, and all the
findings still hold significant based on the permutation tests.
To our knowledge, this is the first report to characterize SChLAP1
expression by ISH in a hospital-based cohort of American men treated
for clinically localized prostate cancer, as well as a rapid autopsy
cohort of patients with lethal mCRPC. We have used a novel ISH
assay to assess SChLAP1 expression on routine surgical pathology
prostate cancer specimens. We note several major findings from this
work. First, we confirm that SChLAP1 is predominantly a nuclear
RNA transcript (Figure 1), which supports in vitro studies of
SChLAP1 in prostate cancer cells and preliminary in situ data [7].
Second, we find that SChLAP1 expression is enriched in metastatic
samples, suggesting that expression of this lncRNA may be
preferentially selected for during prostate cancer progression. Third,
we find that, in clinically localized prostate cancer, SChLAP1
expression is enriched in samples from tumors with high GSs (≥8)
compared to tumors with lower GSs, which also suggests an
association with aggressive disease. Most importantly, however, we
find that SChLAP1 expression is highly predictive of disease
recurrence after prostatectomy and that this observation remains
significant even after adjusting for all major clinicopathologic
covariates (including GS and seminal vesicle invasion, among others).
As such, our work contributes to the growing body of literature
suggesting that lncRNAs are major drivers of cancer biology and,
therefore, clinically important molecular entities. For example, the
Figure 3. High SChLAP1 expression in clinically localized prostate cancer is associated with decreased time to PSA recurrence after
radical prostatectomy. (A) Receiver operating characteristic curve for logistic regression of SChLAP1 expression and PSA recurrence after
radical prostatectomy (area under the curve = 0.668). The threshold which maximizes the sum of sensitivity and specificity corresponds
to a SChLAP1 ISH product score of 100.9. (B) Kaplan-Meier survival curve for PSA recurrence in clinically localized prostate cancer
patients after radical prostatectomy. High SChLAP1 expression is associated with decreased time to PSA recurrence. (C) Graphical
representation of SChLAP1 expression for each individual patient with clinically localized prostate cancer, stratified by GS, with
associated PSA recurrence status. High SChLAP1 expression is associated with high GS (≥8) and PSA recurrence.
Neoplasia Vol. 16, No. 12, 2014 In Situ Hybridization Assay for the lncRNA SChLAP1 Mehra et al. 1125lncRNA HOTAIR has been studied extensively in a wide variety of
tumors and has been shown to be an important risk factor in breast,
colorectal, and other cancers [10,11]. Interestingly, however,
HOTAIR is not significantly associated with prostate cancer [6].
Expression of the lncRNA MALAT1 has also been associated with
poor patient outcomes in lung and hepatocellular cancer [12,13]. In
addition, the lncRNA PCAT1, previously described by our group [6],
has been associated with poor clinical outcome in colorectal cancer
[14]. Our recent work suggests that PCAT1 confers a BRCA-deficient
phenotype via impaired DNA repair in prostate cancer, potentially
contributing to tumorigenesis and disease progression [15]. Ongoing
work on other lncRNAs as potential cancer biomarkers continues to be
an area of high interest for the cancer biology community [16–19].Our own studies have demonstrated that SChLAP1 expression is a
critical driver of aggressive prostate cancer biology.We have previously
shown that SChLAP1 promotes the metastatic phenotype of prostate
cancer cells by interfering with the function of the SWI/SNF tumor
suppressor complex, leading to global dysregulation of oncogenic gene
expression signatures [7]. SChLAP1 expression in prostate cancer cells
is essential for metastasis in mouse models and for hematogenous
spread of cancer cells in chick embryo experiments. In retrospective
multi-institutional studies, we have also shown that SChLAP1
expression is an independent predictor of metastasis for patients
with clinically localized prostate cancer [20].
To date, we are unaware of any other lncRNA ISH assay that is
currently in clinical development for determining cancer outcome. In
Table 2. Association of SChLAP1 Expression with Clinicopathologic Parameters in a Cohort of
Patients with Clinically Localized Prostate Cancer Treated by Radical Prostatectomy.
SChLAP1 ISH Score b100
(n = 127)
SChLAP1 ISH Score ≥100
(n = 33)
P Value
Age, y
≤60 68 (53.5%) 18 (54.5%) 1.000
N60 59 (46.5%) 15 (45.5%)
Race
Black 14 (11.0%) 4 (12.1%) .294
White 104 (81.9%) 24 (72.7%)
Other/unknown 9 (7.1%) 5 (15.2%)
Preoperative PSA, ng/ml
≤7 70 (55.1%) 20 (60.6%) .694
N7 57 (44.9%) 13 (39.4%)
DRE
T1 87 (68.5%) 18 (54.5%) .152
T2 40 (31.5%) 15 (45.5%)
Gland weight, g
≤50 79 (62.2%) 27 (81.8%) .039
N50 48 (37.8%) 6 (18.2%)
Tumor size, cm
≤1.5 69 (54.3%) 17 (51.5%) .846
N1.5 58 (45.7%) 16 (48.5%)
Multifocal
No 29 (22.8%) 8 (26.7%) .639
Yes 98 (77.2%) 22 (73.3%)
GS
b7 37 (29.1%) 4 (12.1%) .017
=7 85 (66.9%) 24 (72.7%)
N7 5 (3.9%) 5 (15.2%)
Surgical margin
Negative 92 (72.4%) 22 (66.7%) .523
Positive 35 (27.5%) 11 (33.3%)
EPE
Negative 102 (80.3%) 21 (63.6%) .063
Positive 25 (19.7%) 12 (36.4%)
SVI
Negative 125 (98.4%) 28 (84.8%) .004
Positive 2 (1.6%) 5 (15.2%)
AJCC N stage
pNX or pN0 115 (90.6%) 27 (90.0%) 1.000
pN1 12 (9.4%) 3 (10.0%)
PSA recurrence
Negative 92 (72.4%) 17 (51.5%) .035
Positive 35 (27.6%) 16 (48.5%)
Path1992
≤3 102 (80.3%) 20 (60.6%) .023
N3 25 (19.7%) 13 (30.4%)
Path1997
b3 102 (80.3%) 20 (60.6%) .023
≥3 25 (19.7%) 13 (39.4%)
DRE, digital rectal examination; EPE, extraprostatic extension; SVI, seminal vesicle invasion.
Note: There were 3 patients missing AJCC N stage and multifocal records; hence, we used 157 patients for
testing AJCC N stage and multifocal, but 160 patients for other parameters.
Table 3. Univariate Cox Regression Analysis.
Covariate Hazard Ratio 95% CI P Value
SChLAP1 ISH score
(≥100 vs b100) 2.343 1.285 4.270 .005
Age, y
(N60 vs ≤60) 1.715 0.984 2.988 .057
Preoperative PSA, ng/ml
(N7 vs ≤7) 2.244 1.279 3.939 .005
Tumor size, cm 1.879 1.075 3.284 .027
Gland weight, g
Gland weight (b50 vs ≥50) 1.499 0.858 2.621 .155
GS
(7 vsb7) 2.558 1.136 5.758 .023
(N7 vsb7) 5.477 1.830 16.394 .002
(≥7 vs b7) 2.757 1.235 6.155 .013
Surgical margin (positive vs negative) 1.991 1.142 3.471 .015
EPE (positive vs negative) 5.235 3.009 9.109 b .001
SVI (positive vs negative) 8.670 3.791 19.850 b .001
AJCC N stage (pN1 vs pN0 or pNX) 0.921 0.330 2.569 .875
DRE (positive vs negative) 1.644 0.944 2.862 .079
Race (white vs black) 1.156 0.457 2.925 .759
Race (other/unknown vs black) 0.751 0.180 3.145 .696
Multifocal (yes vs no) 1.203 0.441 1.568 .568
Path1992 2.230 1.759 2.826 b .001
Path1997 3.379 2.389 4.781 b .001
Table 4. Multivariate Cox Regression Analysis.
Covariate Hazard Ratio 95% CI P Value
SChLAP1 ISH score (≥100 vs b100) 1.99 1.06 3.73 .032
Preoperative PSA 1.05 1.004 1.100 .034
GS (≥7 vs b7) 1.72 0.75 3.95 .202
Surgical margin (positive vs negative) 1.09 0.57 2.08 .785
EPE (positive vs negative) 3.76 2.04 6.93 b .001
SVI (positive vs negative) 1.47 0.47 4.56 .505
CI, confidence interval.
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that high SChLAP1 expression by ISH is an independent risk factor
for disease recurrence has important implications for the management
of early-stage disease. Indeed, although we observe an enrichment of
SChLAP1 expression in tumors with high GSs (≥8), we also observe a
fraction of low-stage, low-grade tumors with high SChLAP1
expression. We are optimistic that SChLAP1 ISH may be able to
identify low-grade prostate cancer with a high risk of recurrence.
Furthermore, our ISH assay has several important advantages for
clinical translation. First, although not the focus of the current study,
we can perform ISH assays on patient biopsy samples. Thus, in the
future, we may be able to determine SChLAP1 expression in different
prostate cancer foci before definitive therapy. Second, ISH assays are
able to assess SChLAP1 expression even when the tumor content is
very low. This is an advantage over RNA-based polymerase chainreaction or microarray analyses, where low tumor content leads to
poor assay performance because of dilution of tumor RNA by stromal
and benign gland RNA.
Given these attributes, we ultimately envision that an ISH assay for
SChLAP1 could be combined with serum PSA and GS for risk
stratification early in disease management and, therefore, potentially
impact clinical decision making for patients (i.e., active clinical
surveillance versus definitive therapy). Additionally, in the post–
radical prostatectomy population, patients with high SChLAP1
expression may benefit from more rigorous clinical surveillance or,
potentially, adjuvant therapy. Although these speculations remain to
be proven, we are hopeful that further studies demonstrate that
detection of SChLAP1 expression improves management and risk
stratification of prostate cancer patients.
Next, we note that SChLAP1 joins several other RNA-based assays
which have become prominent over the past 5 years. In particular,
urine assays for the lncRNA PCA3 and the TMPRSS2-ERG gene
fusion have shown improvements in the diagnosis of prostate cancer
[21]. The PCA3 assay, in particular, has a high sensitivity for prostate
cancer detection, whereas the TMPRSS2-ERG fusion, which is
present in approximately 50% of tumors [22], has a very high
specificity for prostate cancer. We envision that a SChLAP1-based
assay (i.e., ISH) could complement these tests because neither PCA3
nor TMPRSS2-ERG has been shown as a definitive strong prognostic
early-stage biomarker [23–26]. Thus, although SChLAP1 has a poor
sensitivity for cancer overall, its utility as a strong prognostic test
Neoplasia Vol. 16, No. 12, 2014 In Situ Hybridization Assay for the lncRNA SChLAP1 Mehra et al. 1127could complement the PCA3 and TMPRSS2-ERG tests to identify
patients at a high risk for disease recurrence.
Finally, this study has limitations. First, we analyzed a relatively
small number of patients in a single cohort from a single institution.
Larger, multicohort evaluations will be needed to confirm our
findings. Second, further study regarding the relationship between
SChLAP1, serum PSA, and GS will be needed to establish more
specific implementation of SChLAP1 ISH as an assay in the clinical
decision-making algorithm for routine patient care. Third, in this
study we use the primary outcome of biochemical recurrence as a
measure for patient survival. Therefore, additional independent
studies focusing on larger cohorts using PSA recurrence, as well as
prostate cancer–specific death, as an end point may further define the
overall clinical utility of the SChLAP1 ISH assay. Lastly, integration
of SChLAP1 ISH with established multifactor clinical nomograms,
such as the Cancer of the Prostate Risk Assessment (CAPRA-S) score
[27,28], will be important to assess whether SChLAP1 staining
improves the performance of these risk-stratification algorithms.
In summary, we have developed and optimized a novel RNA ISH
approach to detect SChLAP1 expression in routine surgical pathology
prostate cancer specimens. We demonstrate that approximately 16%
of clinically localized prostate cancers in a hospital-based cohort of
American men exhibit high SChLAP1 expression, which is
significantly associated with disease recurrence after prostatectomy.
Furthermore, we observe high levels of SChLAP1 expression in
mCRPC, which lend strong evidence to the idea that high SChLAP1
expression represents an aggressive molecular subtype of prostate
cancer with a susceptibility to evolve into the castration-resistant
metastatic state. Although the current study remains an initial
evaluation of SChLAP1 ISH, we believe that its clinical application as
a prognostic assay for prostate cancer is very promising and warrants
additional, large-scale evaluation to further define its role as a
potential clinical test.
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